Searchable abstracts of presentations at key conferences on calcified tissues

ba0007oc21 | (1) | ICCBH2019

New mouse model with IFITM5 S42L for atypical type VI osteogenesis imperfecta

Guterman Ram Gali , Hedjazi Ghazal , Stephan Chris , Blouin Stephane , Roschger Paul , Klaushofer Klaus , Kozloff Ken , Fratzl-Zelman Nadja , Marini Joan

Objectives: Osteogenesis Imperfecta (OI) is a collagen-related disorder. Type V OI, caused by a recurrent dominant mutation in the plasma membrane protein IFITM5/BRIL, and type VI OI, caused by recessive null mutations in the anti-angiogenic factor PEDF, have distinct features. IFITM5 S40L, reported in six patients, causes severe dominant OI with phenotype and bone histology similar to type VI, rather than Type V, OI. Our objective is to understand the pathway connecting IFITM...

ba0007oc22 | (1) | ICCBH2019

Bone tissue phenotyping reveals increased matrix mineralization, elevated osteocyte lacunar density and altered vascularity in a new OI mouse model carrying a leucine substitution for the BRIL p.Serine42 residue

Hedjazi Ghazal , Guterman-Ram Gali , Blouin Stephane , Roschger Paul , Klaushofer Klaus , Fratzl-Zelman Nadja , Marini Joan C

Objectives: A common feature of nearly all forms of osteogenesis imperfecta (OI) is a hypermineralized bone matrix. Null mutations in SERPINF1, encoding the potent antiangiogenic factor PEDF, lead to type VI OI with excessive osteoid formation, abnormal osteoblast-osteocyte development and increased matrix mineralization. Recently, atypical type VI OI has been delineated, caused by a loss-of-function mutation (p.S40L) in IFITM5 the causative gene for type V OI. The 6 cases rep...